Summary
Introduction

25,26-Dihydroxycholecalciferol
,D,l is a metabolite of cholecalciferol produced by further hydroxylation of . This compound was first isolated from hog plasma (Suda, DeLuca, Schnoes, Tanaka & Holick, 1970) and was later reported to increase intestinal calcium transport in animals (Lam, Schnoes & DeLuca, 1974; Redel, Bell, Bazely, Calando, Delbarre & Kodicek, 1974) . More recent reports have also indicated that it can inhibit the secretion of parathyroid hormone in the goat (Care, Pickard, Papapoulos, O'Riordan & Redel, 1978) . However, very little is known regarding its physiological role or its tissue of origin in man.
We have previously described the development and clinical application of a radioimmunoassay for 1,25-dihydroxycholecalciferol [ 1, ,D,l, the hormonal form of the vitamin (Clemens, Hendy, Papapoulos, Fraher, Care I% O'Riordan, 1979) . The antiserum used in that assay also recognizes 25,26-(OH),D3 and it has therefore been possible to adapt the method and develop a radioimmunoassay for the measurement of this metabolite in human serum. 25,26-(OH),D, was found to be present in the serum from normal and anephric subjects and its circulating concentrations were dependent on the concentrations of its precursor.
Materials and methods
Materials
Chemically synthesized 25S, ,D3] the natural human metabolite (Redel, Bazely, Mawer, Hann & Jones, 1979; 1980), and 25R,26-dihydroxycholecalciferol [25,R,26-(OH) ,D3] were prepared as described previously (Redel, Miravet, Bazely, Calando, Carre & Delbarre, 1977 High-pressure liquid chromatography was performed by using a model LC 204 fitted with a model 6000A pumping system, and a model 440 ultraviolet, fixed wavelength (254 nm) detector [all from Waters Associates (Inst) Ltd, Northwich, Cheshire, U.K.I. Samples were injected via a Rheodyne model 7280 valve (Rheodyne, Berkeley, CA, U.S.A.). Stainless-steel columns (25 cm x 6.2 mm internal diameter) packed with Zorbax-SIL silica were purchased from Dupont Instruments Ltd, Hitchin, Herts., U.K. Highpressure liquid chromatography grade solvents were purchased from Rathburn Chemicals, Walkerburn, Scotland. All other solvents were AnalaR grade and those used for chromatography were redistilled before use. Glassware used in extraction and purification procedures was routinely prerinsed in acetone and rinsed in the working solvent.
Tritiated 25,26-(OH),D3 and 1,25-(OH),D, were synthesized biologically by incubation of [23, (sp. radioactivity, 76 Ci/ mmol, The Radiochemical Centre, Amersham, Bucks., U.K.) with chick kidney homogenates. The specific radioactivity of these biosynthesized metabolites was assumed to be the same as that of tritiated 25-OHD3 as the amounts generated were not sufficient to permit direct determination (Clemens, Fraher, O'Riordan, Little & Dale, 1980) . The identity of each tritiated metabolite was confirmed by co-chromatography with authentic crystalline preparations on highpressure liquid chromatography. Fig. 1 To establish the efficiency of the purification procedures, [3H124, ,D, and [,HI 1,25-(OH),D, (10 000 c.p.m. each) were added to separate serum extracts which were then purified on Sephadex LH 20 and high-pressure liquid chromatography in the usual manner. The carry-over of tritium into the 25,26-(OH),D, eluting fraction on high-pressure liquid chromatography was 0.01% for 25-OHD3 and 0.10% for 24,25-(OH),D,. No radioactivity attributable to 1,25-(OH),D, was detected in the 25,26-(OH),D, region. Therefore contamination of the 25,26-(OH),D, fraction by these metabolites would not be significant. The 25,26-(OH),D, fraction purified from serum extracts was stored at -2OOC in the dark until assay, at which time it was dried under nitrogen and redissolved in 0.5 ml of ethanol. A portion (0.166 ml) of this solution was dried under nitrogen and dissolved in liquid scintillant (0.25% PPO and 0.025% POPOP-Packard in toluene). This sample, along with two portions of tracer added to separate scintillation vials at the beginning of the extraction, was counted for radioactivity in a Packard 3375 Tricarb counter with automatic external standardization. The recovery of [3H125,26-(OH),D, through the extraction and purification procedure assessed in this way averaged 57%. The possibility of quenching of radioactivity by residual lipids after highpressure liquid chromatography was studied by using quench curves and was found not to be significant.
Radioimmunoassay
Into triplicate 9.75 mm x 50 mm glass test tubes were pipetted 10 pl portions of ethanol containing 2000 c.p.m. (24 fmol, 10 pg) of [,HI 1,25-(OH),D, followed by 0.5 ml of phosphate buffer (0.07 mol/l, pH 7.5) containing bovine serum albumin and antiserum 02282 at a dilution of 1 : 75 000. Tubes then received either 50 pl of ethanol alone or 50 pl of ethanol containing varying amounts of unlabelled 25,26-(OH),D, or unknown derived from the serum extracts. A calibration curve was constructed over the range 0.046-3-0 pmol/tube. Nonspecific binding assessed either by including a separate set of tubes which contained tracer, buffer without antiserum and 50 pl of ethanol or by the addition of large amounts of unlabelled 25,26-(OH),D, in the presence of antiserum was low, being between 2 and 4%. After a 24 h incubation at 4OC, bound and free fractions were separated with dextran-coated charcoal as previously described (Clemens, Hendy, Graham, Baggiolini, Uskokovic & O'Riordan, 1978) . After centrifugation, 0.5 ml of the supernatant was solubilized in scintillant 10.5% PPO and 0.01% POPOP in toluene containing 30% (v/v) Triton X 1001. Samples were counted for radioactivity for 10 min each at an efficiency of A displacement curve was obtained by plotting the radioactivity counts bound in the supernatant against the amount of 25,26-(OH),D, added to each tube. In this way, the concentration of 25,26-(OH),D, in the sample could be calculated after correction for losses during the purification procedure.
Measurement of 25-OHD3
Serum 25-OHD3 was measured with a competitive protein-binding assay (Preece, O'Riordan, Lawson . & Kodicek, 1974) . The normal range for this assay is 7.2-79 nmolll and the limit of detection is 1.9 nmol/l. This assay measures both 25-hydroxyergocalciferol (25-OHD,) as well as 25-OHD3 but it has been previously shown that the concentration of 25-OHD2 in serum from normal British adults is low or unmeasurable (Preece, Tomlinson, Ribot, Pietrek, Korn, Davies, Ford, Dunnigan & O'Riordan, 1975; Poskitt, Cole & Lawson, 1979) . ['HI 1, ,D, compared with tubes with no added sterol. Taking this value as the sensitivity of the assay, the limit of detection of the method when a 5 ml sample is extracted would be 96 pmol/l (40 pg/ml).
35-40%.
Results
Sensitivity of assays
Circulating 25,26-(OH),D, in man
In order to evaluate assay variation, a pool of serum was obtained from a healthy subject and frozen in portions. Repetitive purification and radioimmunoassay of serum samples from this pool showed an interassay variation of 17%. When serum samples from this pool were purified in parallel and assayed in one assay, the intraassay variation was 10%.
The accuracy of the method was further assessed by addition of 25,26-(OH),D3 to two samples, increasing their concentrations by 300 pmol/l. These samples were then purified and assayed together with two sera from the same pool which contained only endogenous 25,26-(OH),D,. The samples with no added 25,26-(OH),D, had a mean concentration of 353 pmol/l and those spiked with exogenous sterol had a mean value of 714 pmol/l. In another experiment addition of large amounts of 25-OHD3 (400 nmol/l) and 24,25-(OH),D, (42 nmol/l) to this pool of serum did not significantly affect the measured concentrations of 25,26-(OH),D3. These results support the findings of the tracer studies indicating that the carry-over of other vitamin D metabolites into the assay fraction is negligible.
Radioimmunoassay of 25,26-(OH),D, in
serum from a patient treated with large doses of cholecalciferol (40 000 i.u./day) revealed a concentration of 9.3 nmol/l (3.9 ng/ml). His serum 25-OHD3 concentration was 368 nmol/l (147 ng/ml). Measurement of 25,26-(OH),D, in serial dilutions of the purified serum extract (Fig.  3) showed that all values obtained for these 
Relationship between serum 25-OHD3 and 25,26-(OH)$, concentrations
When the 25,26-(OH),D, concentrations for normal and anephric subjects were related to their serum 25-OHD3 concentrations, a strong positive correlation was observed (Fig. 5) . This was true for both groups considered together (r = 0.81, P , < 0.01) as well as individually (r = 0.81, P<O-OOl for normal; r = 0 -8 9 , P < 0.05 for anephric patients). The slopes of the two regression lines were not significantly different. It has been shown previously that an assay of comparable sensitivity could be achieved with the serum vitamin D-binding protein (Graham, Preece & O'Riordan, 1977) . Nevertheless, the use of either the antibody or the serum binding protein to measure 25,26-(OH),D, in serum requires that the sterol be efficiently separated from other cross-reacting metabolites before assay. In the method described here, 25,26-(OH),D, was purified by chromatography on L . J. Fraher et al.
Sephadex LH 20 followed by high-pressure liquid chromatography. In this way, a very sensitive method was achieved capable of detecting as little as 96 pmol/l of serum.
The mean concentration of 25,26-(OH),D, in serum from healthy adults by radioimmunoassay was 587 pmol/l. This is consistent with our previous estimations using a competitive proteinbinding assay that measured the combined concentrations of 24,25-(OH),D, and 25,26-(OH),D, (Papapoulos, Lewin, Clemens, Hendy & O'Riordan, 1979) . In normal subjects a strong positive correlation was found between circulating 25-OHD3 and 25,26-(OH),D, concentrations. Patients with clinical osteomalacia due to dietary vitamin D deficiency had low or undetectable concentrations of 25,26-(OH),D,. Conversely, the concentration of this dihydroxy metabolite was high in a patient whose serum 25-OHD3 was elevated during treatment with large doses of cholecalciferol. It therefore appears that in man the production of 25,26-(OH),D, is dependent on the concentration of its 25-hydroxylated precursor. Such a relationship has previously been suggested from indirect measurements in studies investigating the metabolism of labelled cholecalciferol in man (Stanbury & Mawer, 1978 . (1979) , the number of subjects they studied was too small to draw any definite conclusions.
The sites of synthesis of 25,26-(OH),D, in man are not yet known though the chick kidney can carry out 26-hydroxylation of 25-OHD3 in uitro (Tanaka, Shepard,' DeLuca & Schnoes, 1978) and indeed has been used to generate the tritiated metabolite for the studies reported here. In order to investigate the importance of the kidney in the production of 25,26-(OH),D, in man, we have measured its concentration in the sera of anephric subjects. Despite the absence of the kidneys, these patients had detectable concentrations of 25,26-(OH),D, in serum which were positively correlated to the circulating concentrations of 25-OHD,. However, when compared with normal subjects these anephric individuals had lower concentrations of 25,26-(OH),D, for a given concentration of 25-OHD3, suggesting that in man the kidney may contribute in part to the total circulating concentration of this metabolite. Another less likely explanation for this difference may be that 25,26-(OH),D, is more susceptible to loss than 25-OHD3 during haemodialysis. Alternatively, if these patients had taken at some stage any multivitamin preparations containing small amounts of ergocalciferol, it might be that 25,26-(OH),D, if formed was not measured. However, it is entirely clear from our studies that extrarenal sites for 26-hydroxylation of 25-OHD3 exist in man.
It is hoped that further application of this assay in conjunction with the assays for other vitamin D metabolites will shed light on the physiological significance of 25,26-(OH),D, in man.
